the engineering of a class of DNA-binding proteins
known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that
recognize a specific DNA sequence Sangamo has created ZFP transcription
factors (ZFP TF(TM)) that can control gene expression and, consequently,
cell function. Sangamo is also developing sequence-specific ZFP Nucleases
(ZFN(TM)) for gene modification. Sangamo has established strategic
partnerships with companies outside of the human therapeutic space
including Dow AgroSciences, Sigma-Aldrich Corporation and several companies
applying its ZFP technology to enhance the production of protein
pharmaceuticals. For more information about Sangamo, visit the company's
web site at
http://www.sangamo.com.
This press release may contain forward-looking statements based on
Sangamo's current expectations. These forward-looking statements include,
without limitation, references to the research and development of novel ZFP
TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF
technology platform, strategic partnerships with collaborators and clinical
trials of ZFP Therapeutics. Actual results may differ materially from these
forward-looking statements due to a number of factors, including but not
limited to, technological challenges, uncertainties relating to the
initiation and completion of stages of ZFP Therapeutic clinical trials for
Sangamo's HIV/AIDS therapeutic development program, Sangamo's ability to
develop commercially viable products and technological developments by our
competitors. See Sangamo's SEC filings, and in particular, the risk factors
described in Sangamo's Annual Report on Form 10-K and its most recent
quarterly report on Form 10-Q. Sangamo assumes no obligation to update the
forward-looking information contained in this press release.
'/>"/>SOURCE Sangamo BioSciences, Inc Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
Sangamo BioSciences Announces Third Quarter Conference Call and Webcast2.
Sangamo BioSciences to Present at Two Upcoming Investor Conferences3.
Sangamo BioSciences to Present at the UBS Global Life Sciences Conference4.
Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference5.
Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference6.
Sangamo BioSciences Reports Second Quarter 2008 Financial Results7.
Sangamo BioSciences Announces Second Quarter Conference Call and Webcast8.
Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals9.
Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants10.
Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration11.
Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference